PANAXIR

PANAXIR is a pharmaceutical-grade sublingual cannabis extract tablet developed by Panaxia Pharmaceutical Industries. The formulation contains the active cannabinoids delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), which function as modulators of the endocannabinoid system by targeting the CB1 and CB2 receptors. Designed for rapid disintegration under the tongue, the sublingual tablet allows for direct absorption through the oral mucosa into the systemic circulation, effectively bypassing first-pass hepatic metabolism. This delivery route enhances bioavailability and provides more consistent pharmacokinetic profiles compared to traditional oral administration. Clinical studies conducted in 2019 indicated that PANAXIR achieves faster absorption and lower inter-patient variance than the oromucosal spray Sativex. The product is intended for a variety of medical indications, including chronic pain, neuropathy, nausea, and spasticity.

Brand names

PANAXIR

Other names

Panaxia sublingual cannabis tabletsCannabis sublingual tabletscannabis extract (sublingual)